Axiom International Investors LLC DE Acquires Shares of 53,190 La Jolla Pharmaceutical Company (LJPC)

Axiom International Investors LLC DE bought a new stake in shares of La Jolla Pharmaceutical Company (NASDAQ:LJPC) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 53,190 shares of the biopharmaceutical company’s stock, valued at approximately $1,588,000. Axiom International Investors LLC DE owned about 0.24% of La Jolla Pharmaceutical Company as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Geode Capital Management LLC increased its stake in shares of La Jolla Pharmaceutical Company by 4.4% in the first quarter. Geode Capital Management LLC now owns 109,933 shares of the biopharmaceutical company’s stock valued at $3,281,000 after buying an additional 4,611 shares during the period. Vanguard Group Inc. increased its stake in shares of La Jolla Pharmaceutical Company by 26.4% in the first quarter. Vanguard Group Inc. now owns 662,285 shares of the biopharmaceutical company’s stock valued at $19,769,000 after buying an additional 138,155 shares during the period. Marshall Wace North America L.P. bought a new stake in shares of La Jolla Pharmaceutical Company during the first quarter valued at approximately $594,000. MARSHALL WACE ASIA Ltd bought a new stake in shares of La Jolla Pharmaceutical Company during the first quarter valued at approximately $594,000. Finally, Monashee Investment Management LLC acquired a new stake in La Jolla Pharmaceutical Company during the first quarter worth about $2,985,000.

Institutional Ownership by Quarter for La Jolla Pharmaceutical Company (NASDAQ:LJPC)

Shares of La Jolla Pharmaceutical Company (NASDAQ LJPC) traded up 0.25% during mid-day trading on Tuesday, reaching $28.10. The company had a trading volume of 513,796 shares. The firm’s market capitalization is $621.66 million. The stock has a 50 day moving average price of $28.83 and a 200 day moving average price of $25.60. La Jolla Pharmaceutical Company has a 12-month low of $14.63 and a 12-month high of $39.28.

La Jolla Pharmaceutical Company (NASDAQ:LJPC) last issued its quarterly earnings results on Thursday, April 27th. The biopharmaceutical company reported ($1.26) earnings per share for the quarter, topping the consensus estimate of ($1.34) by $0.08. La Jolla Pharmaceutical Company had a negative return on equity of 89.72% and a negative net margin of 12,692.37%. On average, equities analysts forecast that La Jolla Pharmaceutical Company will post ($4.89) earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This piece was originally published by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this piece on another website, it was stolen and republished in violation of United States and international trademark and copyright law. The legal version of this piece can be accessed at https://sportsperspectives.com/2017/06/20/axiom-international-investors-llc-de-takes-position-in-la-jolla-pharmaceutical-company-ljpc-updated.html.

A number of equities analysts recently weighed in on LJPC shares. J P Morgan Chase & Co restated a “buy” rating and set a $40.00 target price (up from $27.00) on shares of La Jolla Pharmaceutical Company in a report on Tuesday, February 28th. SunTrust Banks, Inc. reaffirmed a “buy” rating and set a $57.00 price objective (up from $38.00) on shares of La Jolla Pharmaceutical Company in a research report on Monday, February 27th. Jefferies Group LLC reissued a “buy” rating and issued a $40.00 target price on shares of La Jolla Pharmaceutical Company in a research report on Wednesday, March 29th. Chardan Capital boosted their target price on shares of La Jolla Pharmaceutical Company from $80.00 to $90.00 and gave the company a “buy” rating in a research report on Thursday, March 2nd. Finally, Noble Financial reaffirmed a “buy” rating on shares of La Jolla Pharmaceutical Company in a research note on Sunday, April 30th. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. La Jolla Pharmaceutical Company currently has an average rating of “Buy” and a consensus price target of $41.17.

In other news, Director Kevin C. Tang acquired 149,254 shares of La Jolla Pharmaceutical Company stock in a transaction on Thursday, March 23rd. The shares were bought at an average cost of $33.50 per share, for a total transaction of $5,000,009.00. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 26.43% of the company’s stock.

La Jolla Pharmaceutical Company Company Profile

La Jolla Pharmaceutical Company is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies to improve outcomes in patients suffering from life-threatening diseases. LJPC-501 is its formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension (CRH).

Receive News & Ratings for La Jolla Pharmaceutical Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for La Jolla Pharmaceutical Company and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply